# Host Immune Response to Novel RNA COVID-19 Vaccination

> **NCT04784689** · — · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 50 (actual)

## Conditions studied

- COVID-19 Vaccine
- Cancer

## Interventions

- **BIOLOGICAL:** COVID-19 Vaccine

## Key facts

- **NCT ID:** NCT04784689
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-24
- **Primary completion:** 2022-05-18
- **Final completion:** 2022-05-18
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04784689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04784689, "Host Immune Response to Novel RNA COVID-19 Vaccination". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04784689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*